PAREXEL International Corp. (PRXL) Announces Quarterly Earnings Results, Meets Expectations
PAREXEL International Corp. (NASDAQ:PRXL) announced its earnings results on Thursday. The company reported $0.49 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.49, Analyst Ratings Network reports. The company had revenue of $487.10 million for the quarter, compared to the consensus estimate of $479.49 million. During the same quarter in the previous year, the company posted $0.41 earnings per share. The company’s revenue for the quarter was up 15.4% on a year-over-year basis.
PAREXEL International Corp. (NASDAQ:PRXL) opened at 48.03 on Thursday. PAREXEL International Corp. has a one year low of $32.75 and a one year high of $55.02. The stock has a 50-day moving average of $45. and a 200-day moving average of $47.2. The company has a market cap of $2.714 billion and a P/E ratio of 26.65.
A number of research firms have recently commented on PRXL. Analysts at ISI Group upgraded shares of PAREXEL International Corp. from a “buy” rating to a “strong-buy” rating in a research note to investors on Wednesday, January 22nd. They now have a $56.00 price target on the stock, up previously from $53.00. On the ratings front, analysts at Thomson Reuters/Verus downgraded shares of PAREXEL International Corp. from a “buy” rating to a “hold” rating in a research note to investors on Monday, January 20th. Finally, analysts at Thomson Reuters/Verus upgraded shares of PAREXEL International Corp. from a “hold” rating to a “buy” rating in a research note to investors on Tuesday, December 24th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, four have given a buy rating and two have issued a strong buy rating to the company. PAREXEL International Corp. has an average rating of “Buy” and a consensus target price of $51.51.
PAREXEL International Corporation (NASDAQ:PRXL) is a biopharmaceutical services company, providing a range of expertise in clinical research, medical communications, consulting, and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.